To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
L Elizabeth Budde
MD, PhD
City of Hope National Medical Center Duarte, California
Associate Professor, Department of Hematology and Hematopoietic Cell Transplantation, Executive Medical Director, Enterprise Immune Effector Cell Program
TARGET AUDIENCE
These activities are intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
LEARNING OBJECTIVES
- Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for various forms of non-Hodgkin lymphoma, and assess the similarities and differences between currently available agents in this class.
- Evaluate the available clinical research database with CD20 x CD3 bispecific antibodies in the management of diffuse large B-cell lymphoma (DLBCL), and optimally incorporate this approach into current treatment algorithms.
- Evaluate published clinical research data with CD20 x CD3 bispecific antibodies in combination with other systemic therapies, and consider the implications of these findings for DLBCL management.
- Appreciate the clinical and biological factors that guide the selection and sequencing of therapy for patients with relapsed/refractory DLBCL, and use this information to personalize treatment recommendations.
- Recognize adverse events associated with available bispecific antibodies and combination strategies, and implement approaches to educate patients and manage complications.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1 (interview) or 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THESE CME ACTIVITIES
To receive credit for these activities, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation (interview, lecture).
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Budde — Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Janssen Biotech Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Kite, A Gilead Company, Merck.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
These activities are supported by an educational grant from Genentech, a member of the Roche Group.
Release date: September 2026
Expiration date: September 2027
Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood Adv 2026;10(15):5367-77. Abstract
Brody JD et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial. Blood 2025;145(15):1621-31. Abstract
Budde LE et al. Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the phase 3 SUNMO study including in patient subgroups. EHA 2026;Abstract PF968.
Budde LE et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: Primary results of the phase III SUNMO trial. J Clin Oncol 2025;43(36):3799-811. Abstract
Chapuy B et al. Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma. ASH 2025;Abstract 61.
Cheah CY et al. Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial. ASH 2025;Abstract 64.
Crombie JL et al. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma. ICML 2025;Abstract 74.
Fox CP et al. Results from EPCORE DLBCL-1: Randomized phase 3 study of epcoritamab (epcor) vs investigator’s choice chemoimmunotherapy (CIT) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). EHA 2026;Abstract S235.
Hutchings M et al. Efficacy and safety of glofitamab plus polatuzumab vedotin in relapsed/refractory large B-cell lymphoma including high-grade B-cell lymphoma: Results from a phase Ib/II trial. J Clin Oncol 2025;43(36):3788-98. Abstract
Sharman JP et al. Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the phase II MorningSun study. ASH 2025;Abstract 62.